Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
CertaraSeptember 22, 2025
Certara Announces Fall 2025 Certainty Circuit in EMEA, APAC
Join Certara's Fall 2025 Certainty Circuit in EMEA & APAC to explore AI-enabled biosimulation insights,…
CertaraSeptember 17, 2025
Certara Integral: The Master Data Repository Powering Efficient and Collaborative PK/PD Workflows
Charles River improved its global pharmacokinetics workflows by adopting Certara’s Integral as a central data…
CertaraAugust 27, 2025
Differences between eCTD 4.0 and eCTD 3.2.2 Submissions – What You Need to Know
Access our on-demand webinar to explore the key differences between eCTD 4.0 and eCTD 3.2.2.…
CertaraAugust 11, 2025
Certara Reports Second Quarter 2025 Financial Results
RADNOR, PA— August 6, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development,…
CertaraAugust 6, 2025
Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials
GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…
CertaraJuly 31, 2025
